JPRN-jRCT2080221605未知1 期
A Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of TAS-115 in Patients with Advanced Solid Tumors.
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 85
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Signed, written informed consent.
- •- Histologically or cytologically confirmed solid tumor.
- •- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
排除标准
- •- Investigational drug therapy within 28 days prior to enrollment.
- •- Radiotherapy within 21 days prior to enrollment.
- •- Received extensive prior radiotherapy on more than 30% of bone marrow.
- •- Females who are pregnant or breastfeeding.
- •- Serious complications.
研究者
相似试验
已完成
1 期
Phase I Study of TAS-115 in Patients with Advanced Solid TumorsJPRN-jRCT2080222284Taiho Pharmaceutical Co., Ltd.90
尚未招募
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MRX-I Tablets in Healthy Adult Subjects (Part 3)This study is for healthy volunteers. The intended use of the investigational product is the treatment of serious gram-positive bacterial infectionsInfection - Studies of infection and infectious agentsACTRN12613001212741CPR Pharma Services24
尚未招募
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MRX-I Tablets in Healthy Adult Subjects (Part 2)This study is for healthy volunteers. The intended use of the investigational product is the treatment of serious gram-positive bacterial infectionsInfection - Studies of infection and infectious agentsACTRN12613001211752CPR Pharma Services12
尚未招募
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MRX-I Tablets in Healthy Adult Subjects (Part 1)This study is for healthy volunteers. The intended use of the investigational product is the treatment of serious gram-positive bacterial infectionsInfection - Other infectious diseasesACTRN12613001206718CPR Pharma Services30
进行中（未招募）
不适用
To determine a safe and tolerable dose of palifermin in pediatric subjects of different age groups when administered once daily for 3 consecutive days before and 3 consecutive days after a myeloablative chemo-radiotherapy conditioning regimen with allogeneic hematopoietic stem cell transplant (HSCT).EUCTR2015-002526-39-Outside-EU/EEASwedish Orphan Biovitrum AB (publ)54